Forge Biologics Announces Closing of $120 Million Series B Financing
29.4.2021 15:00:00 EEST | Business Wire | Press release
Forge Biologics, a gene therapy-focused contract development and manufacturing organization, today announced the closing of a $120 million Series B financing. The financing was led by RA Capital Management with participation from Perceptive Advisors and related affiliates, Surveyor Capital (a Citadel company), Octagon Capital, and Marshall Wace. Existing investors Perceptive Xontogeny Venture Fund and Drive Capital also participated. In connection with the financing, Matthew Hammond, Ph.D., of RA Capital, and Fred Callori of the Perceptive Xontogeny Venture Fund will join the Company’s Board of Directors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210429005365/en/
“We are very pleased to be working with RA Capital and a strong syndicate of top-tier life sciences investors who share our vision as we now advance our growth as a global gene therapy manufacturing and development company,” said Timothy J. Miller, Ph.D., CEO, President and Co-Founder of Forge Biologics. “We have built Forge into a focused gene therapy development engine with a firm commitment to helping our clients provide potentially life-saving gene therapies to patients. We believe that focusing entirely on gene therapy will allow us to best serve our clients and patients by efficiently delivering high quality product.”
Forge will use the proceeds of this Series B financing to accelerate the expansion of its AAV manufacturing CDMO capabilities with cGMP production capacity, as well as operate its subsidiaries that are advancing novel AAV gene therapy programs. Forge brings a patients-first approach to accelerate the development of transformative medicines for those who need them most and is addressing the growing demand for gene therapy manufacturing capacity. Through its currently-operational 175,000 square foot cGMP facility in Columbus, Ohio, dedicated to AAV viral vector manufacturing, Forge offers end-to-end manufacturing services, including research and toxicology grade AAV production, to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing.
“The success of complex biologics like AAV is exhausting existing manufacturing capacity around the industry. This financing will help to address this industry-wide capacity shortage by properly capitalizing an emerging gene therapy-focused CDMO capable of producing high quality cGMP product for its clients,” said Matthew Hammond, Ph.D., principal at RA Capital Management. “We are confident that Forge’s experienced team will become the trusted partner of innovative therapeutics companies, working collaboratively with clients to successfully deliver AAV manufacturing solutions.”
Through its subsidiaries, Forge is also working to advance a proprietary pipeline of novel gene therapies, including its lead program FBX-101 for the treatment of patients with Krabbe disease, a first-in-human gene therapy utilizing an adeno-associated virus (AAV) to deliver a functioning copy of the GALC gene intravenously to cells in the central nervous system (CNS) and peripheral organs.
Chardan Capital Markets acted as exclusive placement agent for the offering, with Ice Miller acting as legal advisor.
About Forge Biologics
Forge Biologics is a hybrid gene therapy contract manufacturing and therapeutic development company. Forge’s mission is to enable access to life changing gene therapies and help bring them from idea into reality. Forge has a 175,000 square foot facility in Columbus, Ohio, “The Hearth,” to serve as its headquarters. The Hearth is the home of a custom-designed cGMP facility dedicated to AAV viral vector manufacturing and will host end-to-end manufacturing services to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing. By taking a patients-first approach, Forge aims to accelerate the timelines of these transformative medicines for those who need them the most.
For more information, please visit https://www.forgebiologics.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210429005365/en/
Contact information
Media Inquiries:
Dan Salvo
Director of Communications and Community Development
Forge Biologics Inc.
media@forgebiologics.com
Business Development:
Magdalena Tyrpien
Vice President and Head of Business Development
Forge Biologics Inc.
BD@forgebiologics.com
Investor Relations
Christina Perry, MSA, CPA
Vice President, Finance and Investor Relations
Forge Biologics Inc.
Investors@forgebiologics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GasEntec Announces New Ownership Structure, Accelerating Next Phase of Global Growth10.9.2026 12:00:00 EEST | Press release
GasEntec Holdings Inc., a global LNG technology and assets company, today announced a new ownership structure designed to accelerate GasEntec’s next phase of growth and expand the commercialization of its proprietary LNG technologies and solutions. A consortium led by the Groupe Mimran has acquired a majority stake in GasEntec Holdings Inc., the US holding company, supporting GasEntec’s global growth. Under the new structure, GasEntec Holdings is the parent company of GasEntec’s South Korean operating business. Prior shareholders have exited in full. GasEntec’s customer relationships, contracts, engineering organization and ongoing global operations remain unchanged. GasEntec will continue to operate independently, with its technology development, engineering and operations centered in South Korea and an expanding commercial presence across global markets. The new structure provides GasEntec with additional capital and strategic resources to build on its history of LNG innovation and p
EUMETSAT Takes Control of MTG-I210.9.2026 10:30:00 EEST | Press release
EUMETSAT’s Mission Control Centre in Darmstadt, Germany, took over control of the newest addition to its fleet of meteorological satellites, Meteosat Third Generation Imager 2 (MTG-I2), on 9 September 2026, following the successful completion of its Launch and Early Orbit Phase (LEOP). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260909889951/en/ MTG-I2 in orbit MTG-I2 launched from Europe’s Spaceport in French Guiana on 27 August 2026 and has now reached its geostationary orbit, around 36,000 km above Earth. During LEOP, carried out for EUMETSAT by Telespazio, communications with the satellite were established, its solar arrays deployed and a series of precise manoeuvres brought it to its designated orbital position. The spacecraft has now been handed over to EUMETSAT’s flight operations teams. EUMETSAT, working with ESA and European industry, will now begin extensive calibration and validation activities to prepare the s
LUMI AI Factory Selects IQM's Staged Path to Europe's First Superconducting Quantum Computer With Logical Qubits10.9.2026 10:08:00 EEST | Press release
IQM Quantum Computers (Nasdaq: IQMX) today announced its upgrade path for a logical-qubit-capable quantum computer. The deployment to the LUMI AI Factory, led by CSC – IT Center for Science, will support R&D efforts toward fault-tolerant quantum computing and advancements in hybrid computing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260910712470/en/ UMI AI Factory selects IQM's staged path to Europe's first superconducting quantum computer with logical qubits The system, named LUMI-IQ, is an integral part of the wider LUMI AI Factory initiative, and is jointly funded by the EuroHPC Joint Undertaking and the participating countries: Finland, Czechia, Norway, and Poland. LUMI-IQ will be hosted in CSC’s new data center in Kajaani, Finland. LUMI-IQ will be delivered in three steps: the first installation of an IQM Halocene H4 system in 2027 with 150 physical qubits and early quantum error correction capabilities. The syste
Cyviz and SWISS Create Flexible Collaboration Hub for Hybrid Work at Scale10.9.2026 10:00:00 EEST | Press release
Cyviz AS has delivered a flexible collaboration hub for Swiss International Air Lines Ltd. (SWISS), designed to support hybrid meetings, workshops, training, town halls, and internal events at scale. The project highlights how global enterprises are investing in reliable, intuitive, and versatile collaboration environments as hybrid work becomes embedded in day-to-day operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260910985990/en/ Inside the SWISS collaboration hub at their headquarters in Zurich Located at SWISS headquarters in Zurich-Kloten, Switzerland, the new collaboration hub demonstrates how enterprise collaboration spaces are evolving from traditional meeting rooms into strategic workplace infrastructure. Delivered by Cyviz, the environment supports a wide range of hybrid formats while making advanced room technology simple for everyday users. Designed to switch seamlessly between separate and combined ro
Nothing Cleans Like Oral‑B iO: The Electric Toothbrush That Cleans Deeper, Smarter and Better10.9.2026 10:00:00 EEST | Press release
Oral‑B, the #1 brand most used by dentists worldwide, today spotlights its most advanced brushing technology: the Oral‑B iO range. Powered by a unique 2-in-1 cleaning technology, iO is engineered to clean deeper into every gap, brush smarter with real-time pressure guidance, and deliver results that are clinically proven to be better. The proof is everything — and nothing cleans like Oral‑B iO. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260904320713/en/ Oral-B iO10 Most people know that an electric toothbrush outperforms a manual one — but not everyone knows why, or what makes one electric brush stand apart from another. Oral‑B iO makes the difference clear: deeper, smarter, better — everywhere. Cleans Deeper: The Technology Behind the Clean At the heart of iO is a unique 2-in-1 technology: ultra-precise round head rotations work together with bristle-generated micro vibrations to break down and remove plaque simultaneou
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom